SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to its active community and ongoing development, including upcoming staking app launch and planned token burns. Community members express excitement about the project's momentum, with some suggesting meetups upon reaching certain market cap milestones. The coin's growing number of watchers and exchange listing contribute to the positive sentiment.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group is trending due to a multi-billion dollar AI infrastructure agreement with Microsoft, sparking excitement and bullish sentiment among investors. The community is actively discussing the potential for significant revenue growth and increased valuation, drawing comparisons to other high-performing AI stocks. This deal validates Nebius as a key player in AI capacity, potentially leading to more partnerships and further expansion.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) is trending due to a significant surge, reportedly linked to news of a private placement and strategic investment related to a crypto initiative. The community is actively discussing the stock's massive intraday gains, potential short squeeze dynamics, and comparisons to other high-flying tickers. Some traders express skepticism, pointing to the company's fundamentals and potential dilution, while others remain bullish, anticipating further upside.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses its future growth drivers beyond car sales, particularly its energy business and upcoming 'Las Megas' event showcasing Megapacks. Concerns are also emerging around declining market share and the impact of expiring EV tax credits, sparking debate about Tesla's valuation and long-term prospects. Sentiment is mixed, with bulls citing potential for AI and robotics while bears point to increasing competition and dependence on subsidies.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid discussions about its solid-state battery technology and recent demonstrations, including its use in a Ducati motorcycle. Community talking points revolve around the long-term potential, partnership with Volkswagen, and speculation regarding additional OEM partners. Increased short interest is adding to the volatility.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending due to its recent verification on Jupiter, a major DEX aggregator within the Solana ecosystem. The community is rallying around this milestone, viewing it as a significant step towards greater trust and visibility. Many are drawing comparisons to early Shiba Inu, highlighting $WAGMI.X's strong community, positive vibes, and potential as a leading culture coin.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

SNTG is trending as traders discuss its potential for a significant run, drawing comparisons to recent surges in similar stocks like OCTO. Community members highlight SNTG's low float and potential for a short squeeze, fueling speculative interest. Some traders are also pointing to a potential for increased borrow fees, which could add pressure on shorts.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to anticipation surrounding an upcoming merger vote, with the community buzzing about the potential for a significant short squeeze and comparing it to other high-momentum plays. Bullish sentiment is fueled by the company's move to become a Bitcoin treasury asset manager and potential access to substantial funding, while others are wary of potential dilution post-merger.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

Forward Industries, Inc. engages in the provision of integrated design, development, and manufacturing solutions for top tier medical and technology customers worldwide. It operates through the following segments: OEM Distribution, Retail Distribution, and Design. The OEM Distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices. The Retail Distribution segment sells smart-enabled furniture and a variety of other products through agreements with various retailers, both in stores and through online retailer websites. The Design segment provides hardware and software product design and engineering services. The company was founded in 1961 and is headquartered in Hauppauge, NY.

Forward Industries, Inc.

Forward Industries ($FORD) is trending due to a recent $1.65 billion private placement to anchor its Solana treasury strategy, sparking discussions about its potential compared to similar plays like $OCTO. The community is focused on the company's lower float and larger treasury relative to its market cap. Some traders are confusing it with Ford Motor Company ($F), while others anticipate a significant price increase following the news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.

Chinese pharmaceutical companies that once supplied ingredients for more than a billion makeshift doses of weight-loss drugs in the U.S. are apparently shifting their focus to generics as regulators crack down on compounded copies of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.Over the past two years, at least eight Chinese firms,&nbsp; including Jiangsu Sinopep-Allsino Biopharmaceutical and Hybio Pharmaceutical, shipped raw semaglutide and tirzepatide to the U.S., according to Reuters’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/chinese-companies-turn-generics-shipments-behind-us-weight-loss-craze-fade-2025-09-02/">report</a>, citing FDA shipping data and public records.&nbsp;Sinopep and Hybio are now reportedly working to develop generic semaglutide, while Nanjing Hanxin Pharmaceutical and Fujian Genohope Biotech may follow.&nbsp;With U.S. law now restricting compounders to personalized doses or formulations not otherwise available, Chinese suppliers are eyeing markets where Novo’s key semaglutide patent is set to expire in 2026, including Canada and Brazil.&nbsp;However, producing semaglutide in&nbsp;its final injectable form is complex, and branded drugmakers could delay generic launches, according to a lawyer for a generic drugmaker.The regulatory shift has already choked supply. In the second quarter of 2025, U.S.-bound&nbsp;shipments of semaglutide and tirzepatide declined by approximately 90% and 34%,&nbsp;respectively, compared to the same quarter a year earlier. That marked a sharp reversal from 2024, when Chinese companies shipped enough semaglutide to make more than one billion starter doses.&nbsp;Novo told the U.S. Commerce Department that in just six months, Chinese exporters sent enough to make 1.5 billion Wegovy doses.The boom began after the FDA declared shortages in 2022, opening the door for compounding pharmacies, often supported by telehealth firms that grew during the pandemic, to sell cheap copies.&nbsp;Never before had a new drug become so wildly popular that the manufacturer simply couldn’t keep up, said Robert Califf, who has led the FDA twice, calling the compounding surge a “once-in-a-decade” issue.The economics were compelling. A 2024 JAMA report estimated&nbsp;that the production cost of&nbsp;semaglutide powder was only $0.07 per month, while Chinese suppliers could sell it at up to seven times that amount.&nbsp;U.S. compounding pharmacies were then able to offer injections at about $230 a month, which is less than half the price of branded versions.The fallout has been costly for Novo Nordisk, which missed quarterly sales targets and saw its shares cut in half in 2025, contributing to the ouster of its CEO in May.As shipments of semaglutide and tirzepatide dry up, some Chinese companies are shifting toward liraglutide, the active ingredient in older Novo drugs Saxenda and Victoza.&nbsp;Generic versions of liraglutide have been available in the U.S. since 2024 and are now promoted by telehealth sites that once pushed semaglutide. A wholesale supplier told Reuters he has seen demand for liraglutide climb.On Stocktwits, retail sentiment was ‘extremely bearish’ for Novo Nordisk and ‘bearish’ for Eli Lilly, with both seeing ‘extremely low’ message volume.While&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 33.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dropped 4.2% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report

As U.S. restrictions tighten, suppliers are targeting markets such as Canada and Brazil, where patents are set to expire in 2026.

Equity

GSK Adds Around $5B in a Month: Here's How to Play the Stock

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

Danish drugmaker Novo Nordisk (NVO) has entered into a multi-year research collaboration with Replicate BioScience to develop new therapeutic candidates, the privately held clinical stage company stated on Thursday.The collaboration will bring together Novo’s therapeutic knowledge and drug development expertise with Replicate’s novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes, and other cardiometabolic diseases, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://replicatebioscience.com/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes/">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> trended within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter about the stock increased by about 157% over the past 30 days. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_10_55_20_AM_png_5dd1ac88ba.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they have purchased more shares of the company.<stembedurl>https://stocktwits.com/bginvest/message/626846711</stembedurl>Under the new deal, Novo Nordisk will receive a defined, exclusive, and worldwide license to use Replicate’s self-replicating RNA platform for the development and commercialization of treatments. Meanwhile, Replicate will receive research funding and is eligible to receive up to $550 million from Novo, including an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the deal.Last month, Novo, which is battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.Last week, it was reported that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, had earlier stated that the company is taking measures to sharpen its commercial execution and ensure efficiencies in cost base while continuing to invest in future growth.NVO stock is down 35% this year and approximately 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/teva-pharma-announces-fda-approval-for-generic-weight-loss-medication/chs6ffWRdmt">This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?

LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.

LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?

Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.

Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?

NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.94	--	--	N/A
Q2 '25	$0.92	--	--	N/A
Q1 '25	$0.91	$0.99	9.16%	BEAT
Q4 '24	$0.83	$0.89	6.80%	BEAT
Q3 '24	$0.88	$0.88	0.19%	BEAT

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest NVO News

NVO Novo Nordisk A/S